OTCMKTS:INTI Inhibitor Therapeutics (INTI) Stock Price, News & Analysis $0.05 +0.00 (+8.00%) As of 06/5/2025 03:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Inhibitor Therapeutics Stock (OTCMKTS:INTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inhibitor Therapeutics alerts:Sign Up Key Stats Today's Range$0.04▼$0.0550-Day Range$0.04▼$0.0652-Week Range$0.03▼$0.10Volume6,350 shsAverage Volume36,322 shsMarket Capitalization$9.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.Read More… Receive INTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INTI Stock News HeadlinesSterol 14 Alpha-Demethylase Inhibitor: 2025 Pipeline Therapeutics Landscape and Growth ProspectsMay 8, 2025 | uk.finance.yahoo.comRAGE Inhibitor Pipeline Insight Report 2025 Analyzes RAGE Inhibitor Drugs, Key Players, and Development ActivitiesApril 30, 2025 | finance.yahoo.comAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. June 6, 2025 | Timothy Sykes (Ad)Dianthus Therapeutics: Complement Therapy Developer With Long Road AheadApril 23, 2025 | seekingalpha.comTonner Drones Obtains Patent For Inhibitor In The United StatesApril 23, 2025 | finance.yahoo.comPeptide screening reveals irreversible inhibitors for cancer's 'undruggable' cJun proteinMarch 21, 2025 | msn.comIndaptus Therapeutics initiates Phase 1 study of Decoy20March 19, 2025 | markets.businessinsider.comNext-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical TestingMarch 12, 2025 | markets.businessinsider.comSee More Headlines INTI Stock Analysis - Frequently Asked Questions How have INTI shares performed this year? Inhibitor Therapeutics' stock was trading at $0.0601 at the beginning of 2025. Since then, INTI shares have decreased by 10.1% and is now trading at $0.0540. View the best growth stocks for 2025 here. How were Inhibitor Therapeutics' earnings last quarter? Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) released its earnings results on Friday, March, 28th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Inhibitor Therapeutics? Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibitor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibitor Therapeutics investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM) and Bank of America (BAC). Company Calendar Last Earnings3/28/2025Today6/06/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:INTI CIK1042418 Webwww.inhibitortx.com Phone(888) 841-6811Fax813-527-0500Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.03 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.65% Return on Assets-40.64% Debt Debt-to-Equity RatioN/A Current Ratio144.77 Quick Ratio144.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book1.80Miscellaneous Outstanding Shares172,574,000Free Float164,344,000Market Cap$9.32 million OptionableNot Optionable Beta-0.43 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:INTI) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredTrump plotting new lockdown?It's listed inside the White House's own documents: Federal Register notice 90 FR 4544 to be exact. And wh...Porter & Company | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredPrepare now for May 31 eventPrepare now for June 30 event This man grew up in a trailer in New Mexico. Today, he's a multimillionaire t...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibitor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.